The devastation and loss of life caused by the wildfires in California this month has been horrifying and upsetting. As well as the terrible destruction at the sites of the wildfires, the resulting impact on air quality has had serious health implications for people hundreds of miles away from the fires themselves. At one point, the air quality in San Francisco was rated the world’s worst as smoke and particles from the fires filled the air.
patientMpower attended the International Congress on Lung Transplantation. It brought together a fantastic range of pulmonologists, nurses, scientists and other professionals from all over the world working to improve outcomes in Lung Transplantation. The topics covered were many and varied, so here we’ve condensed a few takeaways for people considering a lung transplant.
For the latest in our video chats for Pulmonary Fibrosis awareness month, we’re joined by Angela Perillo from the American College of CHEST physicians. Angela talks through different educational activities which CHEST organizes to raise PF awareness, including next month’s annual CHEST meeting in San Antonio Texas.
September is a global month long campaign to help raise awareness of Pulmonary Fibrosis, aid timely diagnosis and help patients with pulmonary fibrosis to get the treatment and care that they need. This is our second Pulmonary Fibrosis chat of the month – & we’re delighted to be joined by Emmy award winner Mike Olsen.
September is a global month long campaign to help raise awareness of Pulmonary Fibrosis, aid timely diagnosis and help patients with pulmonary fibrosis to get the treatment and care that they need. At patientMpower we will be involved in lots of activities for Pulmonary Fibrosis month – This video is the first in our video series for the month. We’re delighted to be joined by Michele Peters from Team Jeffery for PF for our first video of the month.
We are delighted that our app for IPF has been recently been endorsed by the EU-IPFF. The European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) is a non-profit organization that brings together European national patient associations committed to defending their vision of equal access to treatment and care for all IPF patients. They aim to serve as a trusted resource for the IPF community by raising awareness, providing disease education, advancing care, and supporting research for IPF whilst defending the interests of IPF patients at European level.
One of the measurements you can track on the patientMpower app is your oxygen saturation(SpO2), which is measured using a pulse oximeter. Not all people using the patientMpower app currently record their oxygen saturation on the platform, and you may therefore be interested to know more about this feature.
This week I had the opportunity to attend the Lung Health Experience hosted by the American College of Chest Physicians (CHEST) in Chicago. This annual event helps spread awareness of asthma, COPD, lung cancer, pulmonary fibrosis and other lung health initiatives.
patientMpower will be exhibiting at ATS 2018 and we would like to invite you to come and visit us to learn more about our specialist remote patient tracking platforms for Pulmonary Fibrosis and Lung Transplant.
Whether you have only been recently diagnosed with pulmonary fibrosis, or have been diagnosed for a while and are starting to experience new symptoms or have recently started new treatments, it can sometimes feel that pulmonary fibrosis is overwhelming.
My name is Kevin Seals. I am 60 years old and live in Bone Gap, IL. I was diagnosed in October of 2012 with Idiopathic Pulmonary Fibrosis (IPF). I first noticed I had constant fatigue, chills, and leg cramps. I was unable to improve my jogging even after working out for six months.
At patientMpower, we’ve evaluated a lot of fingertip pulse oximeters to measure your Oxygen Saturation (SpO2) – an important objective measure for Pulmonary Fibrosis, IPF, and people with any lung disease. Here are our top 3 devices that we’ve tested.
Hi, my name is Seán O’Muircheartaigh, I’m 73 and located in Galway, Ireland. I was a patient in Galway Regional Hospital with an undiagnosed illness about five years ago. A computed tomography (CT) scan identified by my doctor showed suspicious darkening at the base of my lung. I was transferred to another hospital where they carried out a full scale investigation and confirmed idiopathic pulmonary fibrosis (IPF)
patientMpower for pulmonary fibrosis and lung transplant enables you to keep track of everything relating to your lung health, empowering you to get the best possible outcomes from your treatment and care. Our free app connects to devices you can use at home to track spirometry, pulse oximetry, medication reminders, air quality updates and step counter recording.
Hi, my name is Mike Olsen and I’m from Louisville Kentucky. I am an idiopathic pulmonary fibrosis (IPF) warrior patient. I started having trouble after an ice storm in December 2012. I kept also having allergy problems and when I kept being treated time and time again for sinus infections my allergy doctor sent me to a pulmonologist, because I always had bronchitis every winter.
Hello! My name is Glenda Rouland, I’m from Birmingham, Alabama and I’m 65 years old. I was diagnosed with idiopathic pulmonary fibrosis (IPF) in October of 2015 after I went to see my Doctor because of feeling short of breath.
On behalf of patients across the UK living with Idiopathic Pulmonary Fibrosis (IPF), patientMpower expressed disappointment at NICE’s decision to restrict the use of the antifibrotic pirfenidone (Esbriet) to patients with moderate to severe forms of the disease. NICE recently issued final guidance that pirfenidone is recommended as a treatment option for IPF only if the patient has a forced vital capacity (FVC) between 50% and 80% predicted.